Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for the inhibition of stat5 in prostate cancer cells

Inactive Publication Date: 2007-01-11
GEORGETOWN UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028]FIG. 1C. Adenoviral delivery of dominant-negative Stat5 (AdDNStat5) induced cell death in androgen-independent CWR22Rv human prostate cancer cells. Representative experiment showing a dose-dependent effect on cell viability of adenoviral gene delivery of a dominant-negative Stat5

Problems solved by technology

A central clinical problem in prostate cancer treatment is that residual cancer cells inevitably will overcome androgen ablation, and recur as androgen-independent cancer with increased malignancy.
Furthermore, for established androgen-independent and metastatic prostate cancer, the only current treatment options are radiation and chemotherapy, which both are relatively ineffective and associated with a number of negative side-effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for the inhibition of stat5 in prostate cancer cells
  • Methods and compositions for the inhibition of stat5 in prostate cancer cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0035] Described herein are compositions and methods for inhibiting the growth of prostate cancer cells by inhibiting Stat5 activity. The methods and compositions of the present invention can be used in relation to any type of prostate cancer cell, including, for example, primary prostate cancer cells, advanced prostate cancer cells, and metastatic prostate cancer cells.

[0036] In certain embodiments, the subject invention relates to methods and compositions for treating prostate cancer in a male. In certain embodiments, the invention relates to a method of treating prostate cancer in a male, comprising administering to the male an inhibitor of the activity of Stat5 in prostate cancer cells.

[0037] Identifying regulators of prostate cancer cell survival may lead to new therapeutic strategies for prostate cancer. Applicants report prevalent activation of transcription factor Stat5 in human prostate cancer and provide novel evidence that blocking activation of Stat5 in human prostate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Compositionaaaaaaaaaa
Cell deathaaaaaaaaaa
Cell growthaaaaaaaaaa
Login to View More

Abstract

The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells.

Description

RELATED APPLICATION [0001] This application claims the benefit of priority of U.S. Provisional Application, 60 / 465,014, filed on Apr. 23, 2003, by Marja Nevalainen, entitled “Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer Cells”. The entire teachings of the referenced Provisional Application are hereby incorporated by reference in their entirety.FUNDING [0002] Work described herein was funded, in whole or in part, by National Institutes of Health Grant Numbers RO1 CA83813 and RO1 DK52013 and Department of Defense Grant DAMD 17-01-1-0059. The United States government has certain rights in the invention.BACKGROUND OF THE INVENTION [0003] Currently the only pharmacological strategy for the treatment of prostate cancer is ablation of androgens, either as adjuvant therapy after surgery or as a primary therapy for patients who are deemed unfit for surgery. A central clinical problem in prostate cancer treatment is that residual cancer cells inevitably...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K39/395A61K38/00C12N15/113C12N15/861G01N33/50G01N33/68
CPCA61K38/1709A61K48/00C07K14/4705C07K16/3069C07K16/40C12N2710/10343C12N15/113C12N15/1137C12N15/86C12N2310/11C12N2310/14C07K2316/96A61P35/00
Inventor NEVALAINEN, MARJA T.
Owner GEORGETOWN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com